Ibrutinib in Chronic GVHD : vimarsana.com

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.

Related Keywords

Dana Farber Cancer Institute , Massachusetts , United States , Hannah Choe , Corey Cutler , Bin Chen , Mitchell Horwitz , Cell Therapy Program At Massachusetts , Ohio State University , Marrow Transplant Program At Duke University , Professor Of Medicine At Harvard Medical School , Cell Therapy Program , Massachusetts General Hospital , Harvard Medical School , Stem Cell Transplant Program , Adult Blood , Marrow Transplant Program , Duke University , Assistant Professor , Ohio State , Yi Bin Chen , Chronic Graft Versus Host Disease , Cgvhd , Second Line Treatment , Ruxolitinib , Reach3 Trial , Ibrutinib , Steroid Refractory Cgvhd , Real World Experience , Clinical Trial , Overall Response Rate ,